Skip to main content

Advertisement

SpringerLink
Log in

Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells

  • Original Article
  • Published:
Amino Acids Aims and scope Submit manuscript

Abstract

Traf2- and Nck-interacting kinase (TNIK) is a member of the germinal center kinase family. TNIK was first identified as a kinase that is involved in regulating cytoskeletal organization in many types of cells, and it was recently proposed as a novel therapeutic target in several types of human cancers. Although previous studies suggest that TNIK plays a pivotal role in cancer cell survival and prognosis, its function in hematological cancer cell survival has not been investigated. Here we investigated the relationship between TNIK function and cell viability in multiple myeloma IM-9 cells using TNIK small interfering RNA (siRNA) transfection and dovitinib treatment. Treatment of IM-9 cells with TNIK siRNA and dovitinib treatment reduced cell proliferation. The ATP competing kinase assay and western blot analysis showed that dovitinib strongly inhibited both the interaction of TNIK with ATP (K i, 13 nM) and the activation of Wnt signaling effectors such as β-catenin and TCF4. Dovitinib also induced caspase-dependent apoptosis in IM-9 cells without significant cytotoxicity in PBMCs. Our results provide new evidence that TNIK may be involved in the proliferation of multiple myeloma IM-9 cells and in the anti-cancer activity of dovitinib via inhibition of the endogenous Wnt signaling pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Angevin E, Lopez-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D et al (2013) Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 19:1257–1268

    Article  CAS  PubMed  Google Scholar 

  • Bommert K, Bargou RC, Stühmer T (2006) Signalling and survival pathways in multiple myeloma. Eur J Cancer 42:1574–1580

    Article  CAS  PubMed  Google Scholar 

  • Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G et al (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29:1046–1051

    Article  CAS  PubMed  Google Scholar 

  • Eritja N, Domingo M, Dosil MA, Mirantes C, Santacana M, Valls J et al (2014) Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells. Mol Cancer Ther 13:776–787

    Article  CAS  PubMed  Google Scholar 

  • Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG et al (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329–336

    Article  CAS  PubMed  Google Scholar 

  • Fu CA, Shen M, Huang BC, Lasaga J, Payan DG, Luo Y (1999) TNIK, a novel member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and regulates the cytoskeleton. J Biol Chem 274:30729–30737. doi:10.1074/jbc.274.43.30729

    Article  CAS  PubMed  Google Scholar 

  • Gui J, Yang B, Wu J, Zhou X (2011) Enormous influence of TNIK knockdown on intracellular signals and cell survival. Hum Cell 24:121–126

    Article  CAS  PubMed  Google Scholar 

  • Ho KK, Parnell KM, Yuan Y, Xu Y, Kultgen SG, Hamblin S et al (2013) Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors. Bioorg Med Chem Lett 23:569–573

    Article  CAS  PubMed  Google Scholar 

  • Hu Y, Leo C, Yu S, Huang BC, Wang H, Shen M et al (2004) Identification and functional characterization of a novel human misshapen/Nck interacting kinase-related kinase, hMINK beta. J Biol Chem 279:54387–54397

    Article  CAS  PubMed  Google Scholar 

  • Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F (2002) Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22:1172–1183

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM (2011) Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 17:7451–7461

    Article  CAS  PubMed  Google Scholar 

  • Kim J, Moon SH, Kim BT, Chae CH, Lee JY, Kim SH (2014) A novel aminothiazole KY-05009 with potential to inhibit Traf2- and Nck-interacting kinase (TNIK) attenuates TGF-β1-mediated epithelial-to-mesenchymal transition in human lung adenocarcinoma A549 cells. PLoS One 9:e110180

    Article  PubMed  PubMed Central  Google Scholar 

  • Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111:2962–2972

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)). Method Methods 25:402–408

    Article  CAS  PubMed  Google Scholar 

  • Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M et al (2005) CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 11:5281–5291

    Article  CAS  PubMed  Google Scholar 

  • Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U et al (2002) Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 22:1184–1193

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maestro (2013) version 9.5; Schrödinger LLC, New York

  • Mahmoudi T, Li VS, Ng SS, Taouatas N, Vries RG, Mohammed S et al (2009) The kinase TNIK is an essential activator of Wnt target genes. EMBO J 28:3329–3340

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Majno G, Joris I (1995) Apoptosis, oncosis, and necrosis: an overview of cell death. Am J Pathol 146:3–15

    CAS  PubMed  PubMed Central  Google Scholar 

  • Milowsky MI, Dittrich C, Durán I, Jagdev S, Millard FE, Sweeney CJ et al (2014) Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer 50:3145–3152

    Article  CAS  PubMed  Google Scholar 

  • Porta C, Giglione P, Liguigli W, Paglino C (2015) Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. Future Oncol 11:39–50

    Article  CAS  PubMed  Google Scholar 

  • Ria R, Reale A, Vacca A (2014) Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol 4:73–90

    Article  PubMed  PubMed Central  Google Scholar 

  • Roose J, Huls G, van Beest M, Moerer P, van der Horn K, Goldschmeding R et al (1999) Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. Science 285:1923–1926

    Article  CAS  PubMed  Google Scholar 

  • Schmid I, Krall WJ, Uittenbogaart CH, Braun J, Giorgi JV (1992) Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry 13:204–208

    Article  CAS  PubMed  Google Scholar 

  • Schürch C, Riether C, Matter MS, Tzankov A, Ochsenbein AF (2012) CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. J Clin Invest 122:624–638

    Article  PubMed  PubMed Central  Google Scholar 

  • Shitashige M, Satow R, Jigami T, Aoki K, Honda K, Shibata T et al (2010) Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. Cancer Res 70:5024–5033

    Article  CAS  PubMed  Google Scholar 

  • Shkoda A, Town JA, Griese J, Romio M, Sarioglu H, Knöfel T et al (2012) The germinal center kinase TNIK is required for canonical NF-κB and JNK signaling in B-cells by the EBV oncoprotein LMP1 and the CD40 receptor. PLoS Biol 10:e1001376

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Taira K, Umikawa M, Takei K, Myagmar BE, Shinzato M, Machida N et al (2004) The Traf2- and Nck-interacting kinase as a putative effector of Rap2 to regulate actin cytoskeleton. J Biol Chem 279:49488–49496

    Article  CAS  PubMed  Google Scholar 

  • Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422–426

    Article  CAS  PubMed  Google Scholar 

  • Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184:39–51

    Article  CAS  PubMed  Google Scholar 

  • Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L et al (2001) Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta-catenin signaling is activated in human colon tumors. Proc. Natl Acad Sci USA 9:14973–14978

    Article  Google Scholar 

  • Yu DH, Zhang X, Wang H, Zhang L, Chen H, Hu M et al (2014) The essential role of TNIK gene amplification in gastric cancer growth. Oncogenesis 17:e93

    Article  Google Scholar 

Download references

Acknowledgments

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and by a grant from the Ministry of Science, ICT and Future Planning (NRF-2014R1A1A1002349).

Author information

Authors and Affiliations

  1. Department of Biomedical Laboratory Science, School of Medicine, Eulji University, Daejeon, 34824, Korea

    Hae Jung Chon, Yura Lee, Kyoung Jun Bae & Jiyeon Kim

  2. Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, 46556, USA

    Byung Jin Byun

  3. Department of Pharmacology, School of Medicine, Eulji University, Daejeon, 34824, Korea

    Soon Ae Kim

Authors
  1. Hae Jung Chon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yura Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kyoung Jun Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Byung Jin Byun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Soon Ae Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiyeon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jiyeon Kim.

Ethics declarations

Ethical approval

All procedures that were performed in the studies involving human participants were in accordance with the ethical standards of the International Review Board of Eulji University (EU 15-06), with the 1964 Helsinki declaration and its later amendments.

Conflict of interest

All authors declare that they have no conflict of interest.

Additional information

Handling Editor: G. J. Peters.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (TIFF 635 kb)

Supplementary material 2 (DOCX 115 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chon, H.J., Lee, Y., Bae, K.J. et al. Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells. Amino Acids 48, 1591–1599 (2016). https://doi.org/10.1007/s00726-016-2214-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00726-016-2214-3

Keywords

Search

Navigation